Competing interests
HT
HEART FAILURE, EVENT
KAC reports receiving research grants (to his institution), consultancy, and/or speaking honoraria from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, and Servier; he is listed as an inventor on a patent application by Boehringer Ingelheim for the use of DPP-4 inhibitors in heart failure. HT reports personal fees from the Canadian Medical and Surgical Knowledge Translation Research Group. CDM reports advisory board honoraria/consulting fees from Amgen, AstraZeneca, BioAge, Boehringer Ingelheim and PhaseBio and DSMB stipends from Beth Israel Deaconess Medical Center, Cerus and Takeda. SV reports receiving research grants and/or speaking honoraria from Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly, HLS Therapeutics, Janssen, Novartis, Novo Nordisk, Pfizer, PhaseBio, S&L Solutions Event Management Inc, and Sanofi. SV is the President of the Canadian Medical and Surgical Knowledge Translation Research Group, a federally incorporated not-for-profit physician organization. All other authors have no relevant conflicts of interest to declare.